Showing 3971-3980 of 7279 results for "".
- AbbVie Receives FDA Orphan Drug Designation for Humira for the Investigational Treatment of Moderate-to-Severe Hidradenitis Suppurativahttps://practicaldermatology.com/news/abbvie-receives-fda-orphan-drug-designation-for-humira-for-the-investigational-treatment-of-moderate-to-severe-hidradenitis-suppurativa/2458945/AbbVie announced that the FDA has granted Humira® (adalimumab) orphan drug designation for the investigational treatment of moderate-to-severe hidradenitis suppurativa (HS) (Hurley Stage II and Hurley Stage III disease), a painful, chronic inflammatory skin disease. AbbVie's su
- R. Scott Peterson Is New Head of Medical Affairs at SkinCeuticalshttps://practicaldermatology.com/news/r-scott-peterson-is-new-head-of-medical-affairs-at-skinceuticals/2458946/R. Scott Peterson, PhD has been named Head of Medical Affairs at SkinCeuticals. In his new role at SkinCeuticals, Dr. Peterson will lead the medical affairs team and expand regional scientific services to support the realization of the company's miss
- Viscot Medical Introduces Soffzone Neutral Zone Trayshttps://practicaldermatology.com/news/viscot-medical-introduces-soffzone-neutral-zone-trays/2458950/Intended to reduce the risk of sharps injuries, Viscot Medical’s Soffzone™ Neutral Zone trays were designed by a plastic surgeon for plastic surgeons. According to Viscot, the Soffzone™ Neutral Zone can be easily integrated into a sharps safety
- Murad Partners with AAD to Launch Shade America Programhttps://practicaldermatology.com/news/murad-partners-with-aad-to-launch-shade-america-program/2458951/Murad, Inc. partnered with the American Academy of Dermatology (AAD) to launch Shade America, a new program that will build shade structures in parks and playgrounds across America to provide shade from the sun’s harmful rays. Through the Shade America program, Murad’s goal is to prov
- Galderma to Enter Nutraceutical Markethttps://practicaldermatology.com/news/galderma-to-enter-nutraceutical-market/2458954/Galderma entred into the nutraceutical market through the acquisition of certain assets of Inneov Group. Relevant Inneov products are marketed under the brand names Nutri-Care D, Duocap, Densilogy, Densilogy Men, Fermete, Fermete Aox, Firmness, Pre-Hyaluron 465, Solar and Sun Sensitivity.
- NanoViricides: Topical Anti-Herpes Treatment Dramatically Improves Clinical Symptoms in an Animal Modelhttps://practicaldermatology.com/news/nanoviricides-reports-that-its-topical-anti-herpes-treatment-dramatically-improves-clinical-symptoms-in-an-animal-model/2458963/NanoViricides, Inc., a nanomedicine company developing anti-viral drugs, reports dramatic improvement in clinical symptoms associated with herpes simplex virus infection in the recently completed studies in mice. The studies were performed in the la
- Merck's Pembrolizumab Demonstrates Positive Results in Phase III Study for Advanced Melanomahttps://practicaldermatology.com/news/mercks-pembrolizumab-demonstrates-positive-results-in-phase-iii-study-for-advanced-melanoma/2458959/Merck announced results from the randomized, pivotal Phase III study, KEYNOTE-006, in the treatment of unresectable advanced melanoma. In the study, pembrolizumab was statistically superior to ipilimumab for progression-free survival (PFS), overall survival (OS), and overall response rate (ORR).
- RXi Pharmaceuticals Receives FDA Orphan Drug Designation for Samcyprone for Melanomahttps://practicaldermatology.com/news/rxi-pharmaceuticals-receives-fda-orphan-drug-designation-for-samcyprone-for-melanoma/2458964/The FDA granted RXi Pharmaceuticals Corporation Orphan Drug Designation of its second clinical candidate, Samcyprone™, for the treatment of malignant melanoma Stage IIb to IV. A number of patients with Stage IIb to IV malignant melanoma develop cutaneous metastases. Samcyprone™ is bei
- Provectus Opens Phase 3 Trial Enrollment for Investigational Melanoma Agenthttps://practicaldermatology.com/news/provectus-opens-phase-3-trial-enrollment-for-investigational-melanoma-agent/2458965/Provectus Biopharmaceuticals, Inc. has opened enrollment of patients for its phase 3 international FDA comparative clinical trial of PV-10 for melanoma. The study is an international multicenter, open-label, randomized controlled trial of single-agent intralesional PV-10 versus systemic chemother
- Association of Dermatology Administrators and Managers Names Alice Hyman “Practice Manager of the Year”https://practicaldermatology.com/news/association-of-dermatology-administrators-and-managers-names-alice-hyman-practice-manager-of-the-year/2458966/The Association of Dermatology Administrators and Managers (ADAM) named Alice Hyman of Advanced DermCare in Danbury, CT, the recipient of this year’s Practice Manager of the Year award. She was recognized at the 23rd annual ADAM meeting in San Francisco. Ms. Hyma